Search for Osteoporosis in Women's Health
Physician-authored summaries on the latest research on osteoporosis, editorials on osteoporosis, and perspectives on osteoporosis - drawn from the top medical journals.
- Many women receive inappropriate screening and treatment.
- Schnatz PF et al., Menopause 2011 Oct; 18:1072.
- A Canadian trial showed favorable skeletal effects, but headaches are a concern.
- Jamal SA et al., JAMA 2011 Feb 23; 305:800. Khosla S., JAMA 2011 Feb 23; 305:826.
- Lasofoxifene is unlikely to offer net benefits greater than those of existing therapies.
- Cummings SR et al., N Engl J Med 2010 Feb 25; 362:686. Becker C., N Engl J Med 2010 Feb 25; 362:752.
- Updates to the 2006 recommendations incorporate new findings.
- Bonnick SL et al., Menopause 2010 Jan/Feb; 17:25.
- Biannual subcutaneous denosumab injections prevented vertebral, nonvertebral, and hip fractures.
- Cummings SR et al., N Engl J Med 2009 Aug 20; 361:756. Khosla S., N Engl J Med 2009 Aug 20; 361:818.
- For patients taking corticosteroids, alendronate is more effective than alfacalcidol at preserving bone mineral density.
- de Nijs RN et al., N Engl J Med 2006 Aug 17; 355:675-84.
Powerful tools are available to identify patients at high risk for fracture and to lower that risk.
- August 12, 2010
- Nelson B. Watts, MD
- Women's Health
- Antibody suppresses bone turnover, thereby lowering fracture incidence; cost could be a concern.
- Both high- and low-trauma fractures could indicate underlying osteoporosis.
- Mackey DC et al., JAMA 2007 Nov 28; 298:2381.
- Denosumab injections every 3 or 6 months increased BMD among these postmenopausal women.
- McClung MR et al., N Engl J Med 2006 Feb 23; 354:821-31.
- In two recent NIH-supported clinical trials, investigators examined how to best use parathyroid hormone (PTH) in treating postmenopausal osteoporotic women.
- Black DM et al., N Engl J Med 2005 Aug 11; 353:555-65. Cosman F et al., N Engl J Med 2005 Aug 11; 353:566-75.
- Mixed results from trials of extended bisphosphonate treatment leave treatment and monitoring guidelines uncertain.
- In a randomized, double-blind, placebo-controlled trial, genistein supplementation had a positive effect on BMD.
- Marini H et al., Ann Intern Med 2007 Jun 19; 146:839-47.
- A cost-effectiveness model suggested bisphosphonates should be used only when BMD assessment shows elevated fracture risk.
- Ito K et al., J Clin Oncol 2012 Feb 27;: Dhesy-Thind SK., J Clin Oncol 2012 Feb 27;:
- Bazedoxifene conferred minimal serious adverse effects in two studies; in combination with estrogen, this SERM improved menopausal symptoms.
- Pinkerton JV et al., Menopause 2009 Nov/Dec; 16:1102. Archer DF et al., Menopause 2009 Nov/Dec; 16:1109. Pinkerton JV et al., Menopause 2009 Nov/Dec; 16:1116. Warren MP., Menopause 2009 Nov/Dec; 16:1083.
- Yearly intravenous zoledronic acid was not inferior to daily oral risedronate.
- Reid DM et al., Lancet 2009 Apr 11; 373:1253. Gennari L and Bilezikian JP., Lancet 2009 Apr 11; 373:1225.
- Women with fragility fractures and inadequate osteoporosis treatment were at increased risk for another fracture within a year, with negative effects on quality of life.
- Cooper C et al., Osteoporos Int 2008 Apr; 19:493.
- A once-yearly infusion of zoledronic acid significantly reduced fracture risk in postmenopausal women with osteoporosis.
- Black DM et al., N Engl J Med 2007 May 3; 356:1809-22. Compston J., N Engl J Med 2007 May 3; 356:1878-80.
- Notwithstanding this guidance, HT's role in averting osteoporosis should not be overlooked.
- General information about postmenopausal osteoporosis, a tool you can use to determine your personal fracture risk, and treatments for women at excess risk for fractures